Trials / Completed
CompletedNCT03639935
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Investigators hypothesize that following first-line platinum based chemotherapy, rucaparib in combination with nivolumab, will improve progression-free survival and overall survival in BTC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rucaparib | Rucaparib 600 mg PO BID days 1-28 |
| DRUG | Nivolumab | Nivolumab 240 mg IV days 1 and 15 |
Timeline
- Start date
- 2019-03-28
- Primary completion
- 2023-02-07
- Completion
- 2024-04-30
- First posted
- 2018-08-21
- Last updated
- 2025-06-03
- Results posted
- 2024-08-21
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03639935. Inclusion in this directory is not an endorsement.